162 related articles for article (PubMed ID: 28466360)
1. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Shitara K; Doi T; Nagano O; Fukutani M; Hasegawa H; Nomura S; Sato A; Kuwata T; Asai K; Einaga Y; Tsuchihashi K; Suina K; Maeda Y; Saya H; Ohtsu A
Gastric Cancer; 2017 Nov; 20(6):1004-1009. PubMed ID: 28466360
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
Otsubo K; Nosaki K; Imamura CK; Ogata H; Fujita A; Sakata S; Hirai F; Toyokawa G; Iwama E; Harada T; Seto T; Takenoyama M; Ozeki T; Mushiroda T; Inada M; Kishimoto J; Tsuchihashi K; Suina K; Nagano O; Saya H; Nakanishi Y; Okamoto I
Cancer Sci; 2017 Sep; 108(9):1843-1849. PubMed ID: 28667792
[TBL] [Abstract][Full Text] [Related]
4. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
5. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H; Ryu MH; Kim KP; Ryoo BY; Park SR; Kim BS; Lee IS; Kim HS; Yoo MW; Yook JH; Oh ST; Kim BS; Kang YK
Gastric Cancer; 2017 Nov; 20(6):970-977. PubMed ID: 28303362
[TBL] [Abstract][Full Text] [Related]
7. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
Takayama T; Kubo T; Morikawa A; Morita T; Nagano O; Saya H
Med Oncol; 2016 May; 33(5):45. PubMed ID: 27044355
[TBL] [Abstract][Full Text] [Related]
8. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M
Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.
Kim YH; Chung HC; Kang WK; Park SR; Kim CS; Kim TY; Shin SW; Park BJ; Cha SJ; Bang YJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):263-70. PubMed ID: 17960386
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
Nakayama N; Koizumi W; Sasaki T; Higuchi K; Tanabe S; Nishimura K; Katada C; Nakatani K; Takagi S; Saigenji K
Oncology; 2008; 75(1-2):1-7. PubMed ID: 18719348
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
15. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
16. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer.
Goody RB; MacKay H; Pitcher B; Oza A; Siu LL; Kim J; Wong RK; Chen E; Swallow C; Knox J; Kassam Z; Cummings B; Feld R; Hedley D; Liu G; Krzyzanowska MK; Dinniwell R; Brade AM; Dawson LA; Pintilie M; Ringash J
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):994-1002. PubMed ID: 27745984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]